NIKKEI 225
26,547.05 +119.40 (+0.45%) HANG SENG
19,950.21 +51.44 (+0.26%) CRUDE OIL
114.22 +3.73 (+3.38%) GOLD FUTURES
1,825.20 +17.00 (+0.94%) DOW
32,223.42 +26.76 (+0.08%) BTC-GBP
24,026.18 -757.94 (-3.06%)
Clinigen Group Plc (CLIN.L)
| Previous close | 924.00 |
| Open | 924.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 924.00 - 925.00 |
| 52-week range | 9.25 - 948.05 |
| Volume | |
| Avg. volume | 1,679,225 |
| Market cap | 1.234B |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | 41.48 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.08 (0.82%) |
| Ex-dividend date | 02 Dec 2021 |
| 1y target est | N/A |
- Reuters
UK's Clinigen agrees to sweetened $1.8 billion Triton take-private deal
Shareholders in Clinigen, whose top investor is hedge fund Elliott, will receive 925 pence per share in cash, up from a December bid of 883 pence apiece. New York-based Elliott, which had been raising its holding in Clinigen over the past few months amid reports it was seeking a break-up of the group, owns a 10.5% stake in the British company, according to Refintiv Eikon data. The latest offer by Triley Bidco, a newly created company indirectly owned by Triton Funds, is final and is recommended by the Clinigen board, the companies said in a joint statement.
- Reuters
UK pharmaceutical firm Clinigen agrees to $1.6 billion take-private deal
Clinigen on Wednesday agreed to be bought by UK-based Triton Investment Management in a deal that values the pharmaceutical services group at about 1.2 billion pounds ($1.6 billion), making it the latest British company to go private. Last week, Clinigen confirmed advanced talks with the private-equity firm over a possible deal. Pressure has built on the company since Elliott Management raised its stake in recent weeks amid reports the activist investor was seeking to break up Clinigen.
- Simply Wall St.
Shareholders in Clinigen Group (LON:CLIN) are in the red if they invested three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
